Daily News Analysis

DengiAll

stylish_lining

India's progress with the DengiAll vaccine is a major development in the global fight against dengue, and it highlights the country's growing capability in the field of indigenous vaccine development.

DengiAll: The Indigenous Tetravalent Dengue Vaccine

Development and Collaboration:

  • Developer: The vaccine is developed by Panacea Biotec Limited under a licensing agreement with the National Institutes of Health (NIH), USA.

  • Composition: DengiAll is a tetravalent vaccine, meaning it targets all four types of dengue virus (DENV). It uses a weakened form of the four virus subtypes, with the same virus composition as the vaccine developed by the NIH but with different inactive ingredients.

Clinical Trial Phases:

  • Phase I & II Trials: Initial trials conducted in India showed that the vaccine elicited a balanced and robust immune response against all four types of dengue. The vaccine was also found to be safe and well-tolerated in participants.

    Phase III Trial: India has recently reached the 50% enrolment mark for the Phase III clinical trial, which aims to test the efficacy, immunogenicity, and safety of DengiAll. The trial is being carried out in collaboration with several institutes, including those under the Indian Council of Medical Research (ICMR).

ICMR Institutes Involved:

  • The ICMR-National Institute of Translational Virology (NITVAR) and ICMR-National AIDS Research Institute (NARI) are playing key roles in trial coordination.

    These institutes will ensure that the vaccine's performance and safety are rigorously tested across diverse populations.

Key Facts About Dengue

What is Dengue?

  • Dengue is a mosquito-borne viral infection that occurs mostly in tropical and subtropical regions, particularly in urban and semi-urban areas.

Transmission:

  • The disease is transmitted to humans via the bite of infected Aedes mosquitoes carrying one of the four types of dengue virus (DENV).

    Dengue is not contagious from person to person, except in rare cases where it is passed from a pregnant person to their child.

Symptoms:

  • Common symptoms include:

    • High fever

    • Headache

    • Body aches

    • Nausea

    • Rash

    Dengue Hemorrhagic Fever (DHF): A small proportion of patients may experience severe symptoms leading to Dengue Hemorrhagic Fever, which is life-threatening.

Treatment:

  • There is no specific antiviral treatment for dengue.

    Supportive care is provided to manage symptoms, particularly focusing on pain relief and fever reduction.

Significance of DengiAll's Development

  1. Indigenous Vaccine: This marks a significant step towards self-reliance in vaccine production, with India taking a leading role in the development of a tetravalent dengue vaccine.

  2. Global Health Impact: Dengue is a major health concern in many parts of the world. A successful vaccine can greatly reduce the burden of the disease, especially in endemic regions.

  3. Efforts in Vaccine Development: This project reflects India's ability to develop cutting-edge medical technology in collaboration with global research bodies like NIH, making it an important milestone for Indian scientific innovation.

Conclusion

The DengiAll vaccine trial's success could be a game-changer in the global fight against dengue. The Phase III trial is crucial for determining whether the vaccine can provide long-term protection against all four dengue virus types. India's indigenous capabilities in vaccine development are growing, and DengiAll represents a significant leap toward reducing the public health threat posed by dengue.


 

Gini Coefficient

The Gini coefficient is a key measure used in economics to quantify income inequality within a country or region. Developed by the Italian statistician Corrado Gini, it serves as an essential tool
Share It

Onge Tribe

The Onge tribe, one of the most ancient and primitive tribes of India, is a fascinating yet vulnerable community that resides on Little Andaman Island. Recently, the Andaman and Nicobar Islands ad
Share It

Nipah Virus

Nipah Virus (NiV) is an emerging zoonotic virus that poses a serious health risk due to its high mortality rate and ability to spread through both animal-to-human and human-to-human transmission.
Share It

WHO’s "3 by 35" Initiative

The World Health Organization (WHO) recently launched the "3 by 35" initiative, which aims to reduce the harmful consumption of tobacco, alcohol, and sugary drinks globally. This is part
Share It

Bond Yield

According to Bank of Baroda Research, the yield on India’s benchmark 10-year government bonds is expected to stay soft (low) in July. This indicates stable or easing borrowing costs for the
Share It

VWAP for Institutional Investors

In a move aimed at making trading more transparent and efficient for institutional investors and market participants, SEBI (Securities and Exchange Board of India) has mandated the issuance of a C
Share It

Genome Sequencing

The recent sequencing of the oldest ancient Egyptian genome, dating back 4,500 to 4,800 years, is a groundbreaking achievement in the field of genomics. About the Genome: A genome is the com
Share It

Financial Fraud Risk Indicator (FRI)

Recently, the Reserve Bank of India’s (RBI) directed all Scheduled Commercial Banks, Small Finance Banks, Payments Banks, and Co-operative Banks to integrate the Financial Fraud Risk Indicat
Share It

Very Massive Stars

Very Massive Stars, sometimes referred to as Very Luminous Stars, are celestial giants that possess over 100 times the mass of the Sun. These stars are critical to our understanding of the evoluti
Share It

Right to Privacy

The Madras High Court's judgment quashing the 2011 phone-tapping order issued by the Union Ministry of Home Affairs (MHA) marks a crucial turning point in the interpretation of the right to pr
Share It

Newsletter Subscription


ACQ IAS
ACQ IAS